Abveris announced the release of antibody sequences specific to the SARS-CoV-2 spike (S) protein into the public domain for unrestricted use. Leveraging Alloy Therapeutic's ATX-Gx™ human transgenic mouse platform in parallel with genetically engineered DiversimAb™ mice, Abveris completed concurrent antibody discovery campaigns to develop a diverse panel of unique sequences for potential therapeutic and critical reagent use.
To accelerate the workflow and provide high-content data, Abveris incorporated the use of the Berkeley Lights Beacon® for rapid single B cell screening combined with the Carterra LSA® for high-throughput downstream antibody characterization. The resulting panel of high affinity antibodies span multiple epitopes on the S1 domain (the region of the S protein containing the ACE2 receptor binding domain, which is critical for viral infection). Furthermore, a subset of antibodies exhibits complete blockade of S protein binding to ACE2 and therefore have the potential to serve as viral neutralizing antibodies.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
"As the fight against COVID-19 continues, there are many innovative organizations that can benefit from access to additional tools. We hope the antibodies and corresponding data presented here will empower advanced research," said Tracey Mullen, Chief Executive Office at Abveris. "As experts in antibody discovery and characterization for therapeutic pipelines, we recognize the benefit our antibodies can provide to the scientific community, and we're grateful for our collaborators at Alloy Therapeutics and Carterra for their support in this philanthropic effort."